Abstract
The pharmakokinetic profiles of intraperitoneally infused platinum analogues were determined in 13 women exhibiting minimal residual disease following surgery and systemic chemotherapy for epithelial ovarian cancer or fallopian tube carcinoma by following the disposition of tracer doses of 195mPt radiolabel. Six patients received iproplatin, four were given cisplatin and three received carboplatin. The present data demonstrate no difference in the disposition of total platinum between these three analogues, but differences in the kinetics of free platinum may exist.
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / pharmacokinetics*
-
Carboplatin / administration & dosage
-
Carboplatin / pharmacokinetics*
-
Cisplatin / administration & dosage
-
Cisplatin / pharmacokinetics*
-
Fallopian Tube Neoplasms / drug therapy
-
Fallopian Tube Neoplasms / metabolism
-
Female
-
Humans
-
Infusions, Parenteral / methods
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / pharmacokinetics*
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / metabolism
-
Platinum
-
Radioisotopes
-
Time Factors
Substances
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Radioisotopes
-
Platinum
-
iproplatin
-
Carboplatin
-
Cisplatin